1. Home /
    2. Altai Protocol Library /
  2. New Reference: Pembrolizumab for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Reference: Pembrolizumab for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer

New Reference: Pembrolizumab for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer
Study:
  • Randomised, open-label, phase 3 study (KEYNOTE-177)
  • Untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer
  • Pembrolizumab 200 mg every 3 weeks (N:153) or to the investigator’s choice (N:154)
Efficacy:
  • mOS: NR vs 36·7 months [HR:0·74; 0·53–1·03; p=0·036]
  • mPFS: 16·5 vs 8·2 months [HR 0·59, 95% CI 0·45–0·79]
Safety:
  • Grade >= 3 AEs: 22% vs 66%
  • Grade >= 3 AEs for pembrolizumab: increased ALT (2%), colitis (2%), diarrhoea (2%), and fatigue (2%)
  • Grade >= 3 AEs for chemotherapy: neutropenia (15%), diarrhoea ( 10%), fatigue (9%)

Lancet Oncol. 2022 May;23(5):659-670.

Diaz, Luis A Jr et al. “Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.

https://doi.org/10.1016/s1470-2045(22)00197-8

Reviewed by Hasan Çağrı Yıldırım, MD on May 30, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More